MASSMATRIX INC

Yellow Springs, OH · Biotech · Private

Cloud platform for automated mass spectrometry data analysis of oligonucleotide sequences

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
Yellow Springs, OH
Total capital
$5M
Federal grants
$5M
8 awards · 2019–2025
8.0× sector median 1 award
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2019202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $5M$485K$963K$478K$861K$861K$861K
2019202120232025FEDERAL ↑EQUITY ↓Cumulative $5M$963K$861K$861K$861K

Latest events

  • Federal grantHealth and Human S · Phase I · Advancing Native Mass Spectrometry Analysis with Easier, Faster and More Accurate Intact Mass Deconvolution for Proteins and Nucleic Acids$317K
  • Federal grantHealth and Human S · Phase II · Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences$861K
  • Federal grantHealth and Human S · Phase II · Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences$861K
  • Federal grantHealth and Human S · Phase II · Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences$861K
  • Federal grantHealth and Human S · Phase II · Accelerating Site-specific Characterization of Protein Therapeutics with Novel Machine Learning Methods$478K
  • Federal grantHealth and Human S · Phase II · Accelerating Site-specific Characterization of Protein Therapeutics with Novel Machine Learning Methods$963K
  • Federal grantHealth and Human S · Phase II · Accelerating Site-specific Characterization of Protein Therapeutics with Novel Machine Learning Methods$485K
Show 1 earlier federal award
  • Federal grantHealth and Human S · Phase II · Accelerating Site-specific Characterization of Protein Therapeutics with Novel Machine Learning Methods$142K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing in Biotech · 4373 companies

Line = median
  • Federal contracts#1170 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • ALPH TECHNOLOGIES LLCSimilar federal contract value in Biotech · null in contracts
  • TEZCAT Laboratories LLCSimilar federal contract value in Biotech · null in contracts
  • Epigenetix IncSimilar federal contract value in Biotech · null in contracts
  • ATHGHIN BIOTECHNOLOGY, INC.Similar federal contract value in Biotech · null in contracts
  • GLYCOMANTRA INCSimilar federal contract value in Biotech · null in contracts
  • Vidasym, IncSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .